Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A with the Cartitude-1 Trial

被引：0

作者：

Kamboj, Ishita ^{[1
,2
]}

Chang, Darryl ^{[3
]}

Habib, Alma ^{[4
]}

Vegel, Andrew ^{[5
]}

Struble, Emily ^{[5
]}

Shaikh, Hira ^{[2
,5
]}

Strouse, Christopher ^{[2
,5
]}

Davis, James A. ^{[2
,6
]}

Rashid, Aliya ^{[2
,7
,8
]}

Graf, Kevin ^{[2
,9
]}

Green, Kimberly M. ^{[10
]}

Mushtaq, Muhammad Umair ^{[8
,11
]}

Mahmoudjafari, Zahra ^{[2
,8
]}

Hashmi, Hamza ^{[2
,6
,11
]}

Mcguirk, Joseph P. ^{[8
]}

Abdallah, Al-Ola ^{[2
,8
]}

Atrash, Shebli ^{[2
,12
]}

Khan, Abdullah Mohammad ^{[2
,4
]}

Ahmed, Nausheen ^{[2
,8
]}

机构：

[1] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, MO USA

[2] US Myeloma Innovat Res Collaborat USMIRC, Kansas City, KS USA

[3] Wake Forest Univ, Levine Canc Inst, Sch Med, Atrium Hlth, Charlotte, NC USA

[4] Ohio State Univ, Div Hematol, Columbus, OH USA

[5] Univ Iowa Hosp, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA USA

[6] Med Univ South Carolina, Hollings Canc Ctr, Dept Hematol Oncol, Charleston, SC USA

[7] Univ Kansas Med Ctr, Internal Med, Kansas City, KS USA

[8] Univ Kansas Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS USA

[9] Med Univ South Carolina, Dept Hematol Oncol, Charleston, SC USA

[10] Med Univ South Carolina, Div Hematol Oncol, Charleston, SC USA

[11] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[12] Wake Forest Univ, Atrium Hlth, Sch Med, Levine Canc Inst,Dept Hematol Oncol & Blood Disord, Charlotte, NC USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199187

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：24112 / 24113

页数：2

共 50 条

[41] CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Madduri, Deepu
Berdeja, Jesus G.
Usmani, Saad Z.
Jakubowiak, Andrzej
Agha, Mounzer
Cohen, Adam D.
Stewart, A. Keith
Hari, Parameswaran
Htut, Myo
O'Donnell, Elizabeth
Munshi, Nikhil C.
Avigan, David E.
Deol, Abhinav
Lesokhin, Alexander M.
Singh, Indrajeet
Zudaire, Enrique
Yeh, Tzu-Min
Allred, Alicia J.
Olyslager, Yunsi
Banerjee, Arnob
Goldberg, Jenna D.
Schecter, Jordan M.
Jackson, Carolyn C.
Deraedt, William
Zhuang, Sen Hong
Infante, Jeffrey R.
Geng, Dong
Wu, Xiaoling
Carrasco, Marlene J.
Akram, Muhammad
Hossain, Farah
Rizvi, Syed
Fan, Frank
Jagannath, Sundar
Lin, Yi
Martin, Thomas, III
BLOOD, 2020, 136
[42] Evaluation of Efficacy Outcomes Among Relapsed/ Refractory Multiple Myeloma Treated Patients in a Real-World Setting
Nooka, Ajay
Voorhees, Peter M.
Kumar, Shaji K.
Mehra, Maneesha
Lam, Annette
Slavcev, Mary
Ukropec, Jon
Potluri, Ravi
Dasgupta, Anandaroop
BLOOD, 2017, 130
[43] Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
Martin, Thomas
Usmani, Saad Z.
Berdeja, Jesus G.
Agha, Mounzer
Cohen, Adam D.
Hari, Parameswaran
Avigan, David
Deol, Abhinav
Htut, Myo
Lesokhin, Alexander
Munshi, Nikhil C.
O'Donnell, Elizabeth
Stewart, A. Keith
Schecter, Jordan M.
Goldberg, Jenna D.
Jackson, Carolyn C.
Yeh, Tzu-Min
Banerjee, Arnob
Allred, Alicia
Zudaire, Enrique
Deraedt, William
Olyslager, Yunsi
Zhou, Changwei
Pacaud, Lida
Madduri, Deepu
Jakubowiak, Andrzej
Lin, Yi
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1265 - +
[44] Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.
Usmani, Saad Zafar
Martin, Thomas G.
Berdeja, Jesus G.
Jakubowiak, Andrzej J.
Agha, Mounzer E.
Cohen, Adam D.
Deol, Abhinav
Htut, Myo
Lesokhin, Alexander M.
Munshi, Nikhil C.
O'Donnell, Elizabeth
Jackson, Carolyn Chang
Yeh, Tzu-Min
Banerjee, Arnob
Zudaire, Enrique
Madduri, Deepu
Zhou, Changwei
Bubuteishvili-Pacaud, Lida
Lin, Yi
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up
Sidana, Surbhi
Patel, Krina
Peres, Lauren
Bansal, Radhika
Kocoglu, Mehmet
Atrash, Shebli
Dima, Danai
Smith, Kinaya
Ferreri, Christopher
Midha, Shonali
Dhakal, Binod
Herr, Megan
Nadeem, Omar
Reshef, Ran
Kumar, Anupama
Mann, Hashim
Kalariya, Nilesh
Sborov, Douglas W.
Richard, Shambavi
Khouri, Jack
Martin, Thomas
Htut, Myo
Shune, Leyla
Lin, Yi
Hansen, Doris
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S7 - S8
[46] Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).
Hansen, Doris K.
Patel, Krina K.
Peres, Lauren C.
Kocoglu, Mehmet H.
Shune, Leyla
Simmons, Gary
Ferreri, Christopher J.
Atrash, Shebli
Parrondo, Ricardo Daniel
Chhabra, Saurabh
Costello, Patrick
Midha, Shonali
Alsina, Melissa
Voorhees, Peter M.
Htut, Myo
Sborov, Douglas W.
Khouri, Jack
Janakiram, Murali
Lin, Yi
Sidana, Surbhi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Real-world outcomes of daratumumab monotherapy in relapsed/refractory myeloma
Maouche, N.
Leary, H.
Collings, F.
Tseu, B.
Djebbari, F.
Vallance, G.
Ramasamy, K.
Kothari, J.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 125 - 125
[48] Safety and Efficacy of Teclistamab in Patients with Relapsed/ Refractory Multiple Myeloma: A Real-World Experience
Dima, Danai
Davis, James A.
Ahmed, Nausheen
Jia, Xuefei
Sannareddy, Aishwarya
Shaikh, Hira
Shune, Leyla
Kaur, Gurbakhash
Khouri, Jack
Afrough, Aimaz
Strouse, Christopher
Lochner, Jonathan
Mahmoudjafari, Zahra
Raza, Shahzad
Valent, Jason
Anderson Jr, Larry D.
Anwer, Faiz
Abdallah, Al-Ola
Hashmi, Hamza
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (03): : 308.e1 - 308.e13
[49] A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
Dileo, Rachel
Mewawalla, Prerna
Babu, Kalaivani
Yin, Yue
Strouse, Christopher
Chen, Ethan
Shaikh, Hira
Davis, James A.
Green, Kimberly M.
Alkharabsheh, Omar
Rashid, Aliya
Pokhrel, Bidushi
Ahmed, Nausheen
Abdallah, Al-Ola
Hashmi, Hamza
BLOOD CANCER JOURNAL, 2025, 15 (01):
[50] The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
Nakayama, Hitomi
Aisa, Yoshinobu
Ito, Chisako
Sakurai, Aki
Nakazato, Tomonori
HEMATOLOGY REPORTS, 2024, 16 (04) : 593 - 602

← 1 2 3 4 5 →